7 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds
In this article, we will take a look at some of the small-cap drug manufacturing stocks that are highly favored by hedge funds.
Aquestive Therapeutics Inc. (AQST)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 2,625,000 | $16,957,500 | 0.77% | |
| 2. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 2,500,000 | $16,150,000 | 1.67% | |
| 3. | Millennium Management Israel Englander | 1,535,369 | $9,918,484 | +20% | 0% |
| 4. | Sio Capital Michael Castor | 993,095 | $6,415,394 | -34% | 1.01% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 970,939 | $6,272,266 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.81 | 5,000 | $4,050.00 | 59,532 | 2022-06-14 | Filing | |
| $0.96 | 91,743 | $88,073.28 | 193,702 | 2022-06-08 | Filing | |
| $0.96 | 45,871 | $44,036.16 | 882,871 | 2022-06-08 | Filing | |
| $0.96 | 2,293 | $2,201.28 | 54,532 | 2022-06-08 | Filing | |
| $0.96 | 13,761 | $13,210.56 | 38,761 | 2022-06-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.17 | 29,814 | $124,413.82 | 338,509 | 2026-03-10 | Filing | |
| $4.17 | 180,677 | $753,965.12 | 1,004,753 | 2026-03-10 | Filing | |
| $4.17 | 40,102 | $167,345.65 | 442,879 | 2026-03-10 | Filing | |
| $4.17 | 25,311 | $105,622.80 | 274,867 | 2026-03-10 | Filing | |
| $4.17 | 58,254 | $243,093.94 | 376,112 | 2026-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,000 | $41,500 | 0.01% | |
| 2. | 2,000 | $8,300 | 0% | |
| 3. | 299 | $1,241 | 0% | |
| 4. | 1 | $4 | 0% |
News See All
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Aquestive Therapeutics, Inc. Fourth Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode.
Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay
TheFly reported on February 3 that Lake Street Capital Markets reduced its price target on AQST to $6 from $8 and maintained a Buy rating. This update followed the company's announcement that ...
7 Oversold Pharma Stocks to Buy Now
In 2024, the pharmaceutical sector in the United States was valued at $634.32 billion, and by 2030, it is expected to have grown to $883.97 billion.
Jim Cramer Recently Looked at These 25 Stocks
We're in critical short supply for all sorts of chips that are needed in the data center... It wasn't easy to forecast this boom, I admit, as recently as one year ago.
Jim Cramer Recently Put These 18 Stocks Under a Microscope
“Look out, the year of magical investing may be drawing to a close. All this year, pretty much anybody who bought stocks connected to AI and the data center, well, you know, you made money.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q3 2025 Aquestive Therapeutics, Inc. Earnings Conference Call.
Jim Cramer’s Recent Takes on These 12 Stocks
“I'm talking about the extreme dichotomy between focusing on a body of wisened economists who are being pushed around by a president who wants to run the central bank and focusing on the free ruling...
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Aquestive Therapeutics Second Quarter 2025 Earnings Conference Call.
H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is among the best growth stocks to invest in for the next 5 years. Analysts at H.C.
Hedge Fund Resource Center